Global Orphan Drugs Market Revenue by Drug Types
Global Orphan Drugs Market Revenue Based on Top Selling Drugs
Global Orphan Drugs Market Revenue Based on Therapy Area
Global Orphan Drugs Market Revenue Based on Region
Europe Orphan Drugs Market Revenue by Country
North America Orphan Drugs Market Revenue by Country
Asia Pacific Orphan Drugs Market Revenue by Country
Latin America Orphan Drugs Market Revenue by Country
Middle East & Africa Orphan Drugs Market Revenue by Country
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Orphan Drugs Market Snapshot
Chapter 4. Global Orphan Drugs Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Industry Analysis – Porter’s Five Forces Analysis
4.6. Competitive Landscape & Market Share Analysis
4.7. Clinical Trial/Pipeline Analysis Snapshot
4.8. COVID 19 Impact on Pharmaceutical Industry
Chapter 5. Market Segmentation 1: Drug Types Estimates & Trend Analysis
5.1. Drug Types & Market Share, 2024 & 2034
5.2. Market Size (Value) & Forecasts and Trend Analyses, 2021 to 2034 for the following Drug Types:
5.2.1. Biological
5.2.2. Non-Biological
Chapter 6. Market Segmentation 2: Top Selling Drugs & Trend Analysis
6.1. Top Selling Drugs & Market Share, 2024 & 2034
6.2. Market Size (Value)& Forecasts and Trend Analyses, 2021 to 2034 for the following Top Selling Drugs:
6.2.1. Revlimid
6.2.2. Rituxan
6.2.3. Copaxone
6.2.4. Opdivo
6.2.5. Keytruda
6.2.6. Imbruvica
6.2.7. Avonex
6.2.8. Sensipar
6.2.9. Soliris
6.2.10. Other Top Selling Drugs
Chapter 7. Market Segmentation 3: Therapy Area & Trend Analysis
7.1. Therapy Area & Market Share, 2024 & 2034
7.2. Market Size (Value)& Forecasts and Trend Analyses, 2021 to 2034 for the following Therapy Area
7.2.1. Oncology
7.2.2. Blood
7.2.3. Central Nervous System
7.2.4. Endocrine
7.2.5. Cardiovascular
7.2.6. Respiratory
7.2.7. Immunomodulatory
7.2.8. Other Disease Types
Chapter 8. Orphan Drugs Market Segmentation 4: Regional Estimates & Trend Analysis
8.1. North America
8.1.1. North America Orphan Drugs Market revenue (US$ Million) estimates and forecasts Drug Types, 2021-2034
8.1.2. North America Orphan Drugs Market revenue (US$ Million) estimates and forecasts by Top Selling Drugs, 2021-2034
8.1.3. North America Orphan Drugs Market revenue (US$ Million) estimates and forecasts Therapy Area, 2021-2034
8.1.4. North America Orphan Drugs Market revenue (US$ Million) estimates and forecasts by country, 2021-2034
8.1.4.1. U.S.
8.1.4.2. Canada
8.2. Europe
8.2.1. Europe Orphan Drugs Market revenue (US$ Million) estimates and forecasts by Drug Types, 2021-2034
8.2.2. Europe Orphan Drugs Market revenue (US$ Million) estimates and forecasts by Top Selling Drugs, 2021-2034
8.2.3. Europe Orphan Drugs Market revenue (US$ Million) estimates and forecasts Therapy Area, 2021-2034
8.2.4. Europe Orphan Drugs Market revenue (US$ Million) by country, 2021-2034
8.2.4.1. Germany
8.2.4.2. Poland
8.2.4.3. France
8.2.4.4. Italy
8.2.4.5. Spain
8.2.4.6. UK
8.2.4.7. Rest of Europe
8.3. Asia Pacific
8.3.1. Asia Pacific Orphan Drugs Market revenue (US$ Million) Drug Types, 2021-2034
8.3.2. Asia Pacific Orphan Drugs Market revenue (US$ Million) estimates and forecasts by Top Selling Drugs, 2021-2034
8.3.3. Asia Pacific Orphan Drugs Market revenue (US$ Million) estimates and forecasts Therapy Area, 2021-2034
8.3.4. Asia Pacific Orphan Drugs Market revenue (US$ Million) by country, 2021-2034
8.3.4.1. China
8.3.4.2. India
8.3.4.3. Japan
8.3.4.4. Australia
8.3.4.5. Rest of Asia Pacific
8.4. Latin America
8.4.1. Latin America Orphan Drugs Market revenue (US$ Million) Drug Types, 2021-2034
8.4.2. Latin America Orphan Drugs Market revenue (US$ Million) estimates and forecasts by Top Selling Drugs, 2021-2034
8.4.3. Latin America Orphan Drugs Market revenue (US$ Million) estimates and forecasts Therapy Area, 2021-2034
8.4.4. Latin America Orphan Drugs Market revenue (US$ Million) by country, 2021-2034
8.4.4.1. Brazil
8.4.4.2. Rest of Latin America
8.5. MEA
8.5.1. MEA Orphan Drugs Market revenue (US$ Million) estimates and forecasts Drug Types, 2021-2034
8.5.2. MEA Orphan Drugs Market revenue (US$ Million) estimates and forecasts by Top Selling Drugs, 2021-2034
8.5.3. MEA Orphan Drugs Market revenue (US$ Million) estimates and forecasts Therapy Area, 2021-2034
8.5.4. MEA revenue Orphan Drugs Market revenue (US$ Million) by country, (US$ Million) 2021-2034
8.5.4.1. South Africa
8.5.4.2. Rest of MEA
Chapter 9. Competitive Landscape
9.1. Major Mergers and Acquisitions/Strategic Alliances
9.2. Company Profiles
9.2.1. Bristol-Myers Squibb Company
9.2.2. Celgene Corporation
9.2.3. F. Hoffmann-La Roche Ltd
9.2.4. Amgen
9.2.5. Biogen
9.2.6. Bayer
9.2.7. Novartis AG
9.2.8. GlaxoSmithKline plc
9.2.9. Johnson & Johnson
9.2.10. AbbVie Inc
9.2.11. Eli Lilly and Company
9.2.12. Alexion Pharmaceuticals
9.2.13. Shire
9.2.14. Novo Nordisk
9.2.15. AstraZeneca
9.2.16. Eisai
9.2.17. Daiichi Sankyo
9.2.18. Merck
9.2.19. Teva Pharmaceutical Industries
9.2.20. Actelion Pharmaceuticals Ltd.
9.2.21. Aegerion Pharmaceuticals
Other Prominent Players
This study employed a multi-step, mixed-method research approach that integrates:
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Secondary data for the market study was gathered from multiple credible sources, including:
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Primary interviews for this study involved:
Interviews were conducted via:
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
This ensured that the dataset used for modelling was clean, robust, and reliable.
The bottom-up approach involved aggregating segment-level data, such as:
This method was primarily used when detailed micro-level market data were available.
The top-down approach used macro-level indicators:
This approach was used for segments where granular data were limited or inconsistent.
To ensure accuracy, a triangulated hybrid model was used. This included:
This multi-angle validation yielded the final market size.
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Given inherent uncertainties, three scenarios were constructed:
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.